Dr. Alkhateeb is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2013 - 2017
Indiana University School of MedicineResidency, Internal Medicine, 2009 - 2012
Damascus University Faculty of MedicineClass of 2008
Certifications & Licensure
MN State Medical License 2013 - 2025
IN State Medical License Active through 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) Start of enrollment: 2022 Jun 16
Roles: Contact
- Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases Start of enrollment: 2019 Aug 15
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1 citationsgenotype-based risk stratification outperformsmutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia.Clifford M Csizmar, Mark Gurney, Rashmi Kanagal-Shamanna, Kelly Chien, Danielle Hammond
Haematologica. 2024-10-01 - 89 citationsVenetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patientsErika Morsia, Kristen B. McCullough, Maansi Joshi, Joselle Cook, Hassan B. Alkhateeb
American Journal of Hematology. 2020-12-01 - 10 citationsVenetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxi...Omer Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, Kristen McCullough
American Journal of Hematology. 2024-02-01
Journal Articles
- Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-Grade Myelodysplastic SyndromesHassan Alkhateeb, MD, Anticancer Research
Abstracts/Posters
- Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Ly...Hassan B. Alkhateeb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for LymphomaHassan B. Alkhateeb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition SyndromesHassan B. Alkhateeb, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Authored Content
- Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-Grade Myelodysplastic SyndromesJune 2020
Press Mentions
Molecular Pathology Selected AbstractsJanuary 21st, 2024
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
